Leading Edge Materials Corp. deltar på Aktiespararnas digitala Småbolagsdagar 9 juni kl. 11.00
June 04, 2021 09:08 ET
|
Leading Edge Materials Corp.
Bolagets VD Filip Kozlowski kommer presentera bolaget och projektportföljen på Småbolagsdagarna 2021 torsdagen 9 juni kl. 11:00 som arrangeras digitalt av Aktiespararna Som gruv- och...
Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product, Technology, and End User
June 04, 2021 09:05 ET
|
ReportLinker
New York, June 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By...
Global Online Pharmacy Market Share to Generate Revenues Worth USD 180 Billion by 2026, According to Facts & Factors
June 04, 2021 09:05 ET
|
Facts & Factors
New York, NY, June 04, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Online Pharmacy Market By Product Type (Skin Care, Dental, Cold and Flu, Vitamins,...
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:05 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology...
Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
June 04, 2021 09:05 ET
|
Novartis Pharma AG
Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta...
Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma
June 04, 2021 09:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
June 04, 2021 09:05 ET
|
Ultimovacs ASA
UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData highlighted at ASCO in poster...
Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program
June 04, 2021 09:05 ET
|
Athenex, Inc.
Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxelPost-hoc subgroup efficacy analysis based on updated tumor subtypes in...
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 04, 2021 09:04 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
- September 21, 2024 22:08 ET REJO Solidifies Its Global Footprint with a Prominent Presence at InterTabac 2024
- September 21, 2024 08:33 ET Yeeha! Games Partners with SOMSOC GALLERY to Bridge Web2 and Web3 through Designer Toy Art